Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

This problem is of particular concern in ethnic groups with a high propensity for diabetes and obesity, such as African Americans and Hispanics.

Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

Some participants received a placebo instead of Amylin (Islet Amyloid Polypeptide), giving a reference point.

In the crossover set-up each of the participants took both Amylin (Islet Amyloid Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.

PubMed files the paper under topics including Black or African American, Amyloid, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hispanic or Latino, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide).

The publication is from 2003 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.